Aurobindo Pharma Limited is pleased to announce that the company has got the approval from the US FDA for Cefprozil Tablets USP 250 mg & 500 mg. Cefprozil is a second generation cephalosporin antibiotic. Cefprozil is the generic version  of the brand “Cefzil®”  manufactured and sold by Bristol-Myers Squibb Company Pharmaceutical Research Institute.

Cefprozil is mostly used to treat upper, lower respiratory tract infections and skin infections.

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company has received approvals for most of the targeted API and formulation facilities from leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa. The company’s robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics. 

The formulation portfolio is built on six technology platforms such as immediate release generics, SR/CR generics, Orally disintegrating/Mouth dissolving generics, Combination products, Sterile/Lyophilized generics and Liquids/Dry syrups. Aurobindo has filed over 100 DMFs and 79 ANDAs for the USA market alone in addition to filings in other countries. The pace of filings is matched by rapid product approvals from various markets. Till date Aurobindo received 41 ANDA approvals (both final and tentative) from US alone. Aurobindo operates in over 100 countries and markets over 180 APIs and 250 formulations